RxSight, Inc. (RXST)

Market Cap	1.95B
Revenue (ttm)	89.08M
Net Income (ttm)	-48.61M
Shares Out	36.99M
EPS (ttm)	-1.41
PE Ratio	n/a
Forward PE	144.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	281,302
Open	55.17
Previous Close	54.92
Day's Range	52.65 - 56.40
52-Week Range	17.09 - 58.21
Beta	1.22
Analysts	Strong Buy
Price Target	51.14 (-3.22%)
Earnings Date	May 6, 2024

About RXST

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treat...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 374
• Stock Exchange: NASDAQ
• Ticker Symbol: RXST

Financial Performance

In 2023, RxSight's revenue was $89.08 million, an increase of 81.77% compared to the previous year's $49.01 million. Losses were -$48.61 million, -27.19% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for RXST stock is "Strong Buy." The 12-month stock price forecast is $51.14, which is a decrease of -3.22% from the latest price.

Price Target

$51.14

(-3.22% downside)

Analyst Consensus: Strong Buy